Half of New York Pedestrian Deaths Linked to Substance-Impaired Awareness

A recent retrospective study published in Injury Prevention reveals a significant correlation between substance use and pedestrian fatalities in New York State. Analyzing data from the Fatality Analysis Reporting System between 2018 and 2020, researchers discovered that 44% of pedestrian deaths involved alcohol, drugs, or a combination of both, underscoring a critical public health concern that has been largely overlooked in pedestrian safety campaigns.

The study identifies pedestrian injuries as a leading cause of injury-related death in New York State, with approximately 15,000 annual pedestrian injuries, of which around 3,000 necessitate hospitalization. Despite these alarming figures, public safety initiatives tend to concentrate on impaired driving, leaving pedestrian substance use—particularly its implications for accident risk—understudied.

Using comprehensive fatality data, which includes post-mortem toxicology reports, the researchers found that nearly one in five pedestrian deaths involved drugs alone, while 12% involved simultaneous use of alcohol and drugs. Blood alcohol concentration (BAC) readings above 0.01% were recorded in 14% of the fatalities. The poly-substance use noted is particularly troubling given its association with more profound cognitive impairments than single-substance use, potentially exacerbating hazardous pedestrian behavior.

Demographic patterns emerged from the analysis: men accounted for 63% of the deaths, with the highest proportion of fatalities occurring among those aged 65 and older. Hispanic males exhibited the highest rate of substance-involved deaths at 58%, though over half of the cases lacked complete racial and ethnic data, limiting definitive conclusions.

Temporal trends highlighted that most substance-related pedestrian deaths occurred between 6 p.m. and 6 a.m., peaking on Saturday evenings. Notably, pedestrians who had consumed drugs were more likely to be struck while crossing outside designated crosswalks, suggesting that substance use may impair judgment or risk assessment during street crossing.

The researchers hypothesize that substance use contributes to riskier crossing decisions and, compounded by reduced nighttime visibility, may leave drivers with insufficient reaction time to avoid collisions. However, they emphasize that the presence of substances does not definitively imply causation, acknowledging that testing gaps and data limitations might underestimate the true prevalence of impairment.

This study prompts a call for targeted prevention strategies that address pedestrian substance use, advocating for integrated public health measures promoting safe consumption and travel practices. Developing interventions that mitigate the risks associated with impaired pedestrian behavior could substantially reduce fatal motor vehicle incidents and protect vulnerable populations, particularly older adults and minority groups disproportionately affected.

As pedestrian safety challenges evolve, these findings spotlight a critical, previously underestimated dimension of urban traffic fatalities, urging renewed focus on pedestrian impairment within broader traffic injury prevention frameworks.